Cellular immunotherapies represent a promising approach for the treatment of cancer. Engineered adoptive cell therapies redirect and augment a leukocyte’s inherent ability to mount an immune response by introducing novel anti-tumor capabilities and targeting moieties. A prominent example of this approach is the use of T cells engineered to express chimeric antigen receptors (CARs), which have demonstrated significant efficacy against some hematologic malignancies. Despite increasingly sophisticated strategies to harness immune cell function, efficacy against solid tumors has remained elusive for adoptive cell therapies. Amongst cell types used in immunotherapies, however, macrophages have recently emerged as prominent candidates for the treatment of solid tumors. In this review, we discuss the use of monocytes and macrophages as adoptive cell therapies. Macrophages are innate immune cells that are intrinsically equipped with broad therapeutic effector functions, including active trafficking to tumor sites, direct tumor phagocytosis, activation of the tumor microenvironment and professional antigen presentation. We focus on engineering strategies for manipulating macrophages, with a specific focus on CAR macrophages (CAR-M). We highlight CAR design for macrophages, the production of CAR-M for adoptive cell transfer, and clinical considerations for their use in treating solid malignancies. We then outline recent progress and results in applying CAR-M as immunotherapies. The recent development of engineered macrophage-based therapies holds promise as a key weapon in the immune cell therapy armamentarium.

**Keywords:** CAR (chimeric antigen receptor), solid tumor, adoptive cell immunotherapy, synthetic biology, macrophage/monocyte

**INTRODUCTION**

In recent years, cellular immunotherapy has emerged as a promising approach for treating cancer. These therapies harness the immune system’s capacity to clear foreign pathogens and redirect the response towards tumor associated antigens (TAAs). Cells expressing chimeric antigen receptors (CARs) represent a major class of cellular immunotherapy that program immune cells to recognize TAAs and initiate a targeted antitumor response (1). T cells equipped with CAR (CAR-T) have shown
clinical efficacy in numerous hematological malignancies, leading to the approval of CD19 and BCMA targeted CAR-T products (2).

Although some hematological malignancies have been readily treated by CAR-T, solid tumors present distinct challenges that limit anti-tumor activity. Unlike hematologic malignancies – which allow for disease access in the peripheral blood, bone marrow, lymph nodes, or spleen – solid tumors require active trafficking, extravasation, and penetration into often immunologically cold and dense fibrotic masses. Developing tumors limit T cell recruitment and infiltration, activate broad suppressive pathways to limit T cell activation, and demonstrate heterogenous TAA expression (3–5).

Highlighting the potential of CAR-T against solid tumor targets and the barrier of tumor infiltration, a recent case report demonstrated that anti-HER2 CAR-T were able to clear HER2+ sarcoma that metastasized to the bone marrow – a niche to which CAR-T have access (6). Overwhelmingly, systemic therapy with CAR-T have led to minimal efficacy or transient responses. Numerous efforts have therefore been made to create improved iterations of CAR therapies that overcome solid TME challenges. One approach has been to better equip T cells for the TME using synthetic biology – optimization of CAR framework and signaling domains, deletion of inhibitory receptors with CRISPR, and overexpression of accessory genes such as cytokines, immune ligands, and/or transcription factors (7, 8). Combination therapies with checkpoint inhibitors have also improved CAR-T efficacy, as demonstrated with mesothelin-targeting CAR-T and programmed cell death protein 1 (PD-1) blockade (9).

More recently, significant progress has been made in extending the CAR platform from T cells to alternative leukocytes, such as CAR-expressing NK and gamma-delta (γδ) T cells, whose biological functions may offer improved safety profiles or off-the-shelf potential (10, 11). Compared to conventional CAR-T, these lymphocytes offer reduced risk of alloreactivity, distinct modes of cytotoxicity, and reduced likelihood of cytokine release syndrome (CRS) (11). The success of these novel CAR-lymphocytes raises the question: which immune cells are the best chassis for adoptive CAR immunotherapies? An ideal CAR-immune cell would localize to and persist within the TME while coordinating a broad and robust immune response. The careful choice of immune cell could provide the critical foundation for efficacious CAR therapies, building upon the extensive body of work that has been achieved with CAR-T. Given that CARs have only been tested in a subset of immune cells, continued exploration is warranted to identify the optimum cell type for targeting solid tumors.

Macrophages and other cells of the myeloid lineage could potentially overcome the barriers to treating solid tumors that have hindered CAR-T thus far (12–16). Macrophages are phagocytic cells of the innate immune system that are critical for clearing foreign pathogens (13). Unlike lymphocyte-based therapies, macrophages readily localize to and persist within the TME (14). Macrophages can influence surrounding immune cells in both pro- and anti-inflammatory manners and are adept at remodeling the extracellular matrix (ECM) (13, 15). Macrophages are innate immune cells with potent phagocytic and cytotoxic capabilities that can initiate and potentiate an adaptive immune response via T cell recruitment, antigen presentation, co-stimulation, and cytokine secretion (13, 16). Taken together, these effector functions enable epitope spreading and alleviate challenges from target antigen heterogeneity. In this review, we discuss the application of macrophages as cell therapies for targeting solid tumors. We outline strategies and challenges for engineering antitumor functions in adoptively transferred macrophages. We particularly focus on the design of CAR-Macrophages (CAR-M) and provide a current perspective on the field.

MACROPHAGES FOR TARGETING SOLID TUMORS

Macrophages are capable of numerous effector functions that could support tumor clearance. Their phenotype is highly plastic and exists across a spectrum of pro- and anti-inflammatory states. Several reviews have comprehensively summarized the dichotomous nature of macrophage polarization (17, 18); here, we provide a brief overview of macrophage phenotype for the context of solid tumor therapies. “Classically activated” (M1) macrophages feature a proinflammatory phenotype that is typically induced by IFN-γ from T helper cells Type 1 (Th1). M1 macrophages secrete pro-inflammatory cytokines such as TNF-α, IL-6, IL-12 and IL-1β which can coordinate an immune response and generate reactive oxygen species to facilitate killing of pathogens (19, 20). Through such mechanisms, M1 macrophages have been shown to exhibit increased tumoricidal activities in vitro (21). Activated macrophages upregulate expression of antigen presentation machinery, such as major histocompatibility complex class II (MHC-II), CD80 and CD86, and can thereby serve as antigen presenting cells (APCs) that activate the adaptive immune response by cross-presenting phagocytosed antigens (22–24). Macrophages can thus remove pathogens either directly or by educating the surrounding immune system, both of which would be invaluable for eradicating solid tumors.

In cancer, macrophages often adopt an anti-inflammatory or “alternatively activated” (sometimes referred to as M2) phenotype. Alternatively activated macrophages mediate tissue repair and secrete immunoregulatory cytokines such as IL-4, IL-10, IL-13 and TGF-β, which many solid tumors exploit to support their own growth (25–27). Monocytes are actively recruited to the TME via chemoattractants such as CCL2, where they differentiate into tumor-associated macrophages (TAMs) (28). Within the TME, hypoxia and elevated T helper cells Type 2 (Th2) cytokine levels bias TAMs to express tumor-favoring genes (29–31). TAMs support angiogenesis and increased vascular density, thereby promoting tumorigenesis (32). Furthermore, TAMs favor regulatory T cell responses and suppress effector T cell functions through mechanisms including immunosuppressive cytokine secretion, upregulation of programmed death ligand-1 (PD-1), and enzymatic depletion of L-arginine (33, 34). TAM enrichment in the TME is thus correlated with poor overall prognosis during natural tumor
progression (35). While M1 and M2 macrophage categorization is a significant simplification of the intratumoral phenotypic spectrum, macrophages have a dynamic relationship with the TME, supporting the notion that using synthetic biology to control macrophage phenotype and function has significant potential to drive anti-tumor immunity.

**REPROGRAMMING MACROPHAGES FOR TUMOR SUPPRESSION WITH CELLULAR ENGINEERING**

A crucial challenge when generating macrophage-based cancer therapies is enabling proinflammatory effector functions that persist despite the immunosuppressive TME. Efforts to do so broadly fall into two camps—in situ reprogramming of TAMs, or ex vivo priming of macrophages for adoptive cell transfer. Extensive work has been done on the former to repolarize or deplete TAMs in situ, and this work has recently been reviewed elsewhere (36, 37). Here, we focus on ex vivo manipulations used in adoptive therapies, including pre-treatment with recombinant proteins, expression of therapeutic transgenes, and gene editing with CRISPR-Cas9.

Historically, adoptive macrophage therapies have used recombinant proteins or small molecules to prime immune responses ex vivo (38–42). Earlier studies have shown that IFN-γ treatment enhances macrophage cytotoxicity in vitro (21). The first dose-escalation studies in humans therefore isolated peripheral blood monocytes from patients, cultured and differentiated them into macrophages over the course of 7 days, and primed them with IFN-γ for 18 hours prior to infusion (38, 39). However, IFN-γ-primed macrophages had minimal clinical efficacy and failed to induce significant tumoricidal activity. The adoptive transfer of M1-activated macrophages was well-tolerated by patients, with clinical side effects primarily limited to fever and flu-like symptoms (41). Follow-up studies further showed that radiolabeled macrophages were detected at sites of metastasis for more than 7 days following infusion (43). Collectively, these trials demonstrated the feasibility of manufacturing and safety of delivering billions of autologous macrophages through intravenous administration. Results from these early trials thus provided a critical foundation for adoptive myeloid cell therapies.

Recent approaches have used genetic engineering to design macrophages that express proinflammatory transgenes of interest (12, 44–49). These strategies leverage the tumor-homing tendencies of macrophages to locally deliver therapeutic cargo and induce cytotoxic activity within the tumor niche. For example, IL-12 is a pro-inflammatory cytokine that activates T and NK cells, but its clinical application is hindered by a narrow therapeutic window that precludes safe systemic administration (50). Multiple groups have attempted to overcome the limitations of IL-12 cytokine therapy by recombiantly expressing the cytokine within genetically engineered macrophages (GEMs) or myeloid cells (GEMys) (44, 45). Preclinical models demonstrated that GEMs and GEMys were able to activate a T cell response and prolong survival without inducing systemic toxicity. Similarly, studies have used GEMs to locally deliver interferon α (IFN-α) or IL-21, which promote immune cell activation, or soluble transforming growth factor receptor II (TGFβR2), which impedes TGFβ-mediated immunosuppression (46, 47). Whereas these approaches stimulate the immune system in a constitutive manner, other studies have focused on confining cytotoxicity to antigen-specific contexts. Gardell et al. engineered antigen-specific killing using GEMs that secrete a bispecific T cell engager (BiTE), which creates a functional bridge between T cell receptors and mutated epidermal growth factor receptor variant III (EGFRvIII) on glioblastoma cells (48). BiTE-secreting GEMs facilitated antigen-specific killing by T cells, which was further augmented by the groups work on IL-12 GEMs (44). Cha et al. similarly targeted EGFR by encoding a secreted single-chain variable fragment (scFv) fused to a Fc moiety, which opsonized tumor cells and induced antibody-dependent cellular phagocytosis (ADCP) by macrophages (49). Notably, engineered macrophages can deliver cargo other than genetically encoded proteins; for example, Huang and colleagues used nanoparticles to engineer macrophages that carry photo-sensitive cytotoxic agents, which are released and induce immunogenic cell death upon exposure to near infrared light (51).

Rather than overexpressing transgenes, inhibiting gene expression using CRISPR-Cas9, zinc finger nucleases, and TALENs have been utilized to augment CAR-T and NK cell function (52–54). Recently, there has been increasing interest in gene editing human myeloid cells, and several nucleofection-based methods for transiently delivering CRISPR-Cas9 ribonucleoproteins (RNPs) to primary myeloid cells have been employed (55, 56), as well as specialized methods using nanoparticles to deliver Cas9 plasmid or RNPs (57, 58). Attractive targets for gene editing include regulatory proteins that block anti-tumor functions, such as signal regulatory protein-α (SIRPα). Cancer cells expressing CD47 stimulate macrophage SIRPα to generate a “don’t eat me” signal to evade phagocytosis (59), and the SIRPα/CD47 signaling axis is now a well-established checkpoint in tumor immunity (60). Ray et al. therefore performed a SIRPα knockout (KO) in the murine monocyte/macrophage cell line RAW264.7 using CRISPR-Cas9 and demonstrated that SIRPα-KO macrophages in this system exhibited enhanced phagocytic ability against cancer cells in vitro (58). A subsequent study by Ban et al. demonstrated the therapeutic potential of SIRPα-KO macrophages using syngeneic in vivo models and SIRPα-deficient mice (61). The authors in this study demonstrated that SIRPα-deficient macrophages gained potent anti-tumor properties and coordinated a robust immune response when delivered in combination with radiotherapy (61). Similarly promising results were generated by Myers et al. upon targeting the tyrosine phosphatase Shp1, which signals downstream of SIRPα to propagate anti-phagocytic signals (62). Instead of irreversibly editing genes, numerous CRISPR-based technologies regulate gene transcription using a catalytically dead Cas9 (dCas9) and chromatin remodeling factors (63). For example, Liu et al. silenced CD45, CD209 and TICAM1 genes in primary human monocytes using CRISPR interference (CRISPRi), wherein dCas9 is fused to a KRAB domain (64). Dong et al. used dCas9 fused to a histone methylase to
epigenetically silence hypoxia inducible factor 1 subunit alpha (Hif1α), which mediates TAM immunosuppressive functions (65). When tested in a murine melanoma model, their Hif1α Epigenetically Repressed Macrophage ("HERM") was able to reprogram the tumor’s immunosuppressive microenvironment and prolong survival (65).

CAR-M: MACROPHAGES TAKE THE WHEEL

CARs provide a flexible platform for directing immune cell effector functions towards antigen-expressing tumor cells and can promote macrophage antitumor capabilities. Initial studies demonstrating the success translating the synthetic receptors to macrophages are summarized in Figure 1.

Designed, Sealed, and Delivered; Producing CARs for Expression in Macrophages

Current efforts to engineer CAR-M have found that basic CAR design principles from the T cell field hold true for macrophage biology. Traditional CARs are modular transmembrane proteins consisting of an extracellular antigen-recognition domain, a hinge domain, and one or more cytoplasmic signaling domains (1, 66). We have demonstrated that CARs comprising an scFv against broadly representative targets CD19, HER2, and mesothelin, a CD8 hinge and transmembrane domain, and the CD3ζ intracellular domain efficiently redirect macrophages, guiding antigen dependent phagocytosis, cytokine release, and anti-tumor activity (67). Macrophages expressing CARs with CD3ζ, but not with CD3ζ deletions/tyrosine mutations, killed and phagocytosed tumor cells in an antigen-specific manner. Although CD3ζ is canonically used in CARs due to its role in T cell activation, its cytosolic domain bears significant homology with the macrophage-native Fc receptor common gamma chain (FcRγ) that drives ADCP, though with 3 ITAM domains. We confirmed that CAR-M constructed with either the CD3ζ or FcRγ activating domain were functionally similar in phagocytosis assays, conversely complementing earlier findings showing that CD3ζ- and FcRγ-based chimeric receptors were comparably capable of activating T cells (66).

Indeed, the choice of signaling domain is of particular interest when designing CAR-M, and several groups have explored alternative domains. Morrissey et al. designed CAR-M by screening cytoplasmic domains from murine phagocytic receptors including multiple EGF-like-domains protein 10 (Megf10), FcRγ, adhesion G protein-coupled receptor B1 (Bai1) and tyrosine-protein kinase Mer (MerTK) (68). Primary murine macrophages expressing the FcRγ- or Megf10-based CAR exhibited antigen-specific phagocytic capabilities. Niu et al. designed anti-C-C chemokine receptor type 7 (CCR7) CAR-M to target a newly identified LD30CCR7hi immunosuppressive cell population (69). Their design utilized CCL19, the natural ligand of CCR7, as the receptor’s antigen-recognition domain, rather than an scFv. For the intracellular domain, they evaluated activation domains from MerTK, toll-like receptor 2 (TLR2), TLR4, TLR6 and the CAR-T second-generation 4-1BB-CD3ζ. When screened

![Figure 1](https://example.com/figure1.png)
in the RAW264.7 cell line, CAR-M bearing the MerTK activation domain exhibited the greatest tumor cell toxicity. Interestingly, while anti-CCR7 MerTK-based CAR-M performed well in this context, Morrissey et al’s anti-CD19 CAR bearing the same cytotoxic domain was unable to bind antigen-functionalized beads, despite expression at the cell surface (68). Such discrepancies hint that optimization and careful functional evaluation is necessary when generating new CAR-M architectures. In a final example, Zhang et al. designed a CAR bearing the activation domain from CD147 (CAR-147), a protein that regulates matrix metalloproteinase (MMP) expression and ECM remodeling (70). Instead of triggering phagocytosis, CAR-147 targeted the tumor ECM by upregulating expression of MMPs upon antigen recognition. While CD147 itself is not macrophage-specific, the utilization of this CAR design allowed for CAR-dependent secretion of MMPs within the tumor. These studies collectively illustrate that the modular CAR template can customize how macrophages respond to target antigens. Future efforts to engineer CAR-M will likely tap into the plethora of sophisticated CAR designs that have been developed for T cells, incorporating tandem activation domains (71), multi-antigen logic gates (72, 73), or drug-sensitive modules (74–76).

Delivering CARs and other transgenes to macrophages can present a challenge for researchers, but recent advances in gene delivery have enabled several viral and non-viral strategies for doing so. Myeloid cells are proficient at detecting and responding to foreign nucleic acids (77), making macrophages and monocytes resistant to genetic manipulation. Bobadilla et al. created novel HIV-1-derived lentiviral particles capable of infecting myeloid cells by leveraging the viral accessory protein Vpx (78). Upon infection, Vpx mediates degradation of SAMHD1, a myeloid-specific HIV-1 restriction factor that inhibits lentiviral transduction by limiting the deoxynucleotide pool and preventing efficient reverse transcription (79). The group demonstrated that modified lentiviral virions containing Vpx can efficiently deliver transgenes to myeloid cells. The Vpx platform can accommodate any pre-existing HIV-based lentiviral vector and thus provides an accessible strategy for modifying myeloid cells (47, 64, 78). Given that macrophages have limited proliferative capacity, we hypothesized that non-integrating, replication-deficient adenoviral vectors may allow for efficient and long-term transduction. However, human myeloid cells do not express the Coxsackie adenovirus receptor, which serves as the primary docking site for traditional Ad vectors. Monocytes and macrophages highly express CD46, which mediates docking of group B adenoviruses such as Ad35 (80, 81). We thus evaluated the replication-incompetent chimeric adenoviral vector Ad5F35 and demonstrated that Ad5F35 exhibited robust transduction of primary human macrophages and monocytes – with CAR% and viability routinely >80% (67, 82). Ad5F35-transduced macrophages maintained CAR expression for at least 1 month in vitro and at least 62 days in vivo, as measured by co-expression of CAR-P2A-luciferase. Notably, Ad5F35 activated the macrophage inflammasome and provided a beneficial pro-inflammatory priming signal, which synergized with CAR activity and rendered the CAR-M locked into an M1 phenotype (83). Such results highlight the prospect of leveraging, rather than evading, the inflammatory response that can occur when delivering genetic material.

Several non-viral strategies have also been developed for engineering monocytes and macrophages. The bacterial origin of plasmid DNA can contribute to inflammation and gene silencing. Plasmids devoid of unmethylated cytosine-phospho-guanine (CpG) dinucleotides – a signature of bacterial DNA – were shown to evade detection by TLR9 and exhibit prolonged gene expression in RAW 264.7 macrophages and primary murine BMDMs (49). Other work has optimized the transient delivery of mRNA to monocytes and macrophages, carefully selecting mRNA modifications and transfection reagents to minimize transfection-induced macrophage toxicity or activation (84, 85). Lastly, transposon systems, which enable non-viral integration into the host genome, have been explored in porcine aortic macrophages (86).

Macrophages may be sourced through several production pipelines. While proof-of-concept studies can be performed in model cell lines such as THP1 and Raw 264.7 or with primary/immortalized murine BMDM, clinical translation necessitates a scalable source of primary human cells. For autologous cell therapies, 2-3x10⁹ peripheral blood monocytes can be obtained by leukapheresis (87), and mobilization with filgrastim or sargramostim further increases the number of available monocytes by approximately threefold (88). Our CAR-M therapy is manufactured over 1 week using filgrastim-mobilized CD14+ monocytes (67). Monocytes are cultured and differentiated in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF), which is associated with a pro-inflammatory differentiated phenotype (67, 89). Cells are then transduced with CAR-encoding Ad5F35, which further cements a pro-inflammatory phenotype. To further accelerate manufacturing time, a rapid, same day CAR monocyte process has been developed which yields CAR+ CD14+ monocytes with the capacity to differentiate into M1 CAR-M or CAR-expressing dendritic cells (CAR-DC) (82). Macrophages may be attractive as allogeneic cell therapies since there is no risk of graft versus host disease. Immune cells derived from induced pluripotent stem cells (iPSCs) hold potential as a renewable, allogeneic source for CAR-M therapies. Zhang et al. generated iPSC-derived CAR-Macrophones (CAR-iMac) by reprogramming PBMC’s into iPSC’s over the course of several weeks, transducing with CAR-encoding lentivirus, then differentiating into macrophages following a 4-week differentiation process (90). CAR-iMacs were capable of antigen-dependent macrophage functions, such as cytokine secretion and phagocytosis in vitro. However, CAR-iMacs differentiated with the current protocol had a lingering anti-inflammatory phenotype, and efficacy was limited when tested in murine models. Additionally in oncology applications, a significant consideration with iPSC-derived CAR-M is MHC-matching; antigen cross-presentation is likely an important component of CAR-M activity downstream of TAA engagement, thus careful study is required to determine whether CAR-M derived from MHC knockout iPSCs can potentiate a sufficient anti-tumor T cell response.
Furthermore, continued optimization of the iPSC-to-macrophage differentiation protocol, method of transduction, method of phenotype control, and GMP scale-up are necessary to translate these early findings into the clinic. Provided the process is appropriately scaled, there is theoretically no limit to the number of macrophages that can be expanded from iPSCs or differentiation intermediates, though current optimized protocols yield 2-6×10⁷ macrophage progenitors per harvest (91). Benchmarking iPSC-derived macrophage phenotype against bona fide macrophages will be critical for advancing this approach to CAR-M production.

Mechanisms of Tumor Control by CAR-M

CAR-M therapies are able to clear tumor cells in vitro and in preclinical in vivo models. In vitro, human CAR-M exhibit antigen-specific phagocytosis, cytokine/chemokine secretion, and killing of target antigen expressing targets (67). In two immunodeficient NSGS xenograft models, a single dose of anti-HER2 CAR-M reduced tumor burden and prolonged overall survival against HER2+ SKOV3 tumors. Furthermore, IV-administered CAR-M localized to tumors in several xenograft models and persisted in tumor-free mice (primarily within the liver) for at least 62 days, detected by whole-body bioluminescent imaging of CAR-P2A-luciferase. RNA sequencing revealed that Ad5f35 transduction induced a proinflammatory profile resembling that of classically activated M1 macrophages, which resisted polarization by M2-inducing cytokines in vitro. Furthermore, supernatant from CAR-M was sufficient to induce a proinflammatory phenotype in cultured M2 macrophages. These phenotypic results held true in a humanized immune system (HIS) solid tumor xenograft model, where adoptively transferred CAR-M maintained a durable M1 phenotype and induced pro-inflammatory gene expression in host macrophages. In vitro analysis further showed that CAR-M could coordinate an antitumor T cell response by recruiting T cells and cross-presenting antigens from phagocytosed cells. Recently, our group established an immunocompetent, syngeneic CAR-M model and demonstrated that murine CAR-M increased intratumoral T cell infiltration, NK cell infiltration, dendritic cell infiltration/activation, and TIL activation (92). We found that CAR-M locally administered in HER2+ tumors simultaneously controlled growth of contralateral HER2-negative tumors and prevented antigen-negative relapse upon HER2-negative tumor rechallenge, indicating epitope spreading and induction of long-term immune memory. Notably, this work also demonstrated for the first time that CAR-M synergize with PD1 blockade in PD1-monotherapy resistant solid tumor models (92).

Tumor killing by CAR-M was similarly achieved by Niu et al. using CCR7-targeting CAR-M in the RAW264.7 cell line (69). These CAR-M, which exhibited antigen-specific cytotoxicity in vitro, prolonged survival and prevented metastasis to distal tissues in a 4T1 breast cancer model. CAR-M recruited CD3+ T cells and decreased PD-L1+ cells in the tumor site, confirming that engineered macrophages themselves are not the sole driver of the antitumor response. Adoptive macrophage therapy also increased levels of pro-inflammatory cytokines IL1-β, IL-6, and TNF-α in the serum, indicative of a systemic immune response (69).

CAR-M’s ability to facilitate an immune response was underscored by the CAR-147 technology, which targeted the tumor ECM rather than tumor cells directly (70). Zhang and colleagues hypothesized that degrading the dense tumor ECM would improve immune cell infiltration and thereby trigger antitumor activity. CAR-M engineered with a CD147 cytosolic domain upregulated MMP expression in an antigen-specific manner in vitro, but exhibited no changes in phagocytosis, killing, or cytokine release. In a HER2+ 4T1 breast cancer model, CAR-M slowed tumor growth by reducing its collagen content, increasing the presence of T cells, and increasing IL-12 and IFN-γ signaling. Taken together, these pioneering studies showcase the ability of CAR-M to infiltrate the tumor niche and initiate a broad anti-tumor response by the host immune system.

DISCUSSION

Toward CAR-M Combination Therapies

Co-administration of pharmacological immunotherapies or chemotherapy could further improve CAR-M efficacy. For example, antibody-based immunotherapies rely on macrophage phagocytosis to stimulate an immune response and could be evaluated for augmenting CAR-M efficacy (93, 94). The Fc region of antibodies binds and stimulates macrophage-expressed Fc receptors, leading to ADCP. Antibodies such as trastuzumab and rituximab thus direct macrophages to phagocytose oponized target cells (95). Antibodies that block phagocytosis-inhibiting signals, such as CD47/SIRPα or the inhibitory Fc receptor FcγRIIB, have enhanced macrophage-mediated immunotherapies (96–98). T cell checkpoint inhibitors blocking PD1 signaling have also been shown to improve macrophage phagocytic capabilities in vivo (99). Given the impact of CAR-M on surrounding immune cells, we therefore hypothesized that CAR-M could synergize with PD1 checkpoint inhibitors. In a syngeneic CT26 model, which resists anti-PD1 monotherapy, we demonstrated that the combination of CAR-M with PD1 blockade indeed additively improved overall survival (92). Chemotherapy or radiation therapy could also synergize with CAR-M by inducing immunogenic cell death (100). The efficacy of combining radiation therapy and engineered macrophages was demonstrated by Bian et al. using SIRPα-KO macrophages (61). Furthermore, it is noteworthy that CAR expression is not mutually exclusive from other engineering manipulations described herein. Therefore, future iterations of CAR-M could likely synergize with gene editing or accessory transgene overexpression.

Clinical studies will be crucial to elucidating the toxicity profile of CAR-M in patients. The FDA-approved anti-CD19 CAR-T products tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel carry black box warnings for CRS and neurotoxicity (101). CRS is driven by significant CAR-T expansion and secretion of pro-inflammatory cytokines for
sustained periods of time in the peripheral blood. Given that CAR-M have limited expansion potential and do not persist in peripheral blood, severe CRS is not expected, and indeed was not seen in older studies of M1 polarized non-engineered macrophages (41). Engineered macrophages have been shown to persist in pre-clinical glioblastoma models without associated toxicity, indicating that CAR-M may safely interact with the central nervous system (44, 47). A particular concern that may be more relevant for CAR macrophages than CAR T cells is that the TME could subvert tumor-localized CAR-M into a tumor-supporting phenotype (102). Although preclinical models suggest the opposite – that CAR-M reprogram the TME (67) – correlative studies in patients will be necessary to understand the bidirectional dynamics. At present, the first-in-human CAR-M Phase I clinical trial is underway using Carisma Therapeutic’s lead product CT-0508 for treating HER2 overexpressing solid tumors (NCT04660929). Results from this Phase I trial and others will provide invaluable insights to guide the design of safe and effective CAR-M therapies.

Outlook: Beyond Oncology
Future therapies using engineered macrophages may extend beyond oncology indications. CAR-T have been shown to target fibrotic cardiac and liver tissues, and CAR-M may be even better suited for acellular pathogenic targets (103, 104). Novel therapies could also leverage macrophage tissue remodeling and anti-inflammatory capabilities, rather than their proinflammatory functions. For example, adoptive transfer of anti-inflammatory macrophages has been shown to reduce fibrotic tissue in liver injury models (105). From remodeling synapses to repairing cardiac tissue, macrophages are ubiquitous in maintaining tissue homeostasis, and their therapeutic application should be compatible with myriad tissue contexts (106, 107). In conclusion, macrophage phenotypic plasticity, when combined with synthetic biology, presents an exciting new platform for therapeutic applications to advance cellular engineering and deliver effective immunotherapies.

AUTHOR CONTRIBUTIONS
CS wrote the article and designed the figure. SG and MK contributed to writing and critically revised the article. All authors contributed to the article and approved the submitted version.

REFERENCES
1. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. New Engl J Med (2018) 379:64–73. doi: 10.1056/nejmra1706169
2. Majzner RG, Mackall CL. Clinical Lessons Learned From the First Leg of the CAR T Cell Journey. Nat Med (2019) 25:1341–55. doi: 10.1038/s41591-019-0564-6
3. Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T-Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther (2020) 28:2320–39. doi: 10.1016/j.ymthe.2020.09.015
4. Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular Networks Controlling T Cell Persistence in Adoptive Cell Therapy. Nat Rev Immunol (2021) 22:1–16. doi: 10.1038/s41577-021-00539-6
5. Beatty GL, O’Hara M. Chimeric Antigen Receptor-Modified T Cells for the Treatment of Solid Tumors: Defining the Challenges and Next Steps. PharmacoI Therapeu (2016) 166:30–9. doi: 10.1016/j.pharmthera.2016.06.010
6. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, et al. Tumor Response and Endogenous Immune Reactivity After Administration of HER2 CAR T Cells in a Child With Metastatic Rhabdomyosarcoma. Nat Commun (2020) 11:3549. doi: 10.1038/s41467-020-17175-8
7. Hou AJ, Chen LC, Chen YY. Navigating CAR-T Cells Through the Solid-Tumour Microenvironment. Nat Rev Drug Discov (2021) 20:531–50. doi: 10.1038/s41573-021-00189-2
8. Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol (2019) 10:128. doi: 10.3389/fimmu.2019.00128
9. Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O’Cearbhaill RE, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab. Cancer Discov (2021) 11:2748–63. doi: 10.1158/2159-8290.cd-21-0407
10. Rezvani K, Rouce R, Liu E, Shipp F. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther (2017) 25:1769–81. doi: 10.1016/j.ymthe.2017.06.012
11. Morandi F, Yazdanfar M, Cocco C, Bertaina A, Airoldi I. Engineering the Bridge Between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells. Cells (2020) 9:1757. doi: 10.3390/cells9081757
12. Biglari A, Southgate TD, Fairbairn L, Gilham DE. Human Monocytes Expressing a CEA-Specific Chimeric CD64 Receptor Specifically Target
24. Hume DA. Macrophages as APC and the Dendritic Cell Myth. *J Immunol* (2008) 181:5829–35. doi: 10.4049/jimmunol.181.9.5829

25. Biswas SK, Alvanova P, Mantovani A. Tumor-Associated Macrophages: Functional Diversity, Clinical Significance, and Open Questions. *Semin Immunopathol* (2013) 35:585–600. doi: 10.1007/s00281-013-0367-7

26. Qian B-Z, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. *Cell* (2010) 141:39–51. doi: 10.1016/j.cell.2010.03.014

27. Pollard JW. Tumour-Educated Macrophages Promote Tumour Progression and Metastasis. *Nat Rev Cancer* (2004) 4:1–7. doi: 10.1038/nrc1256

28. DeNardo DG. Macrophage Function in Cancer. *Sci Transl Med* (2016) 8:379pm10. doi: 10.1126/scitranslmed.aaf1446

29. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Taw

30. Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA. Increased Immune Suppressive Activity by Tumor-Associated Macrophages Enhances Tumor-Specific CD8+ T-Cell Function. *J Immunother Cancer* (2020) 8:302. doi: 10.1002/jjic.20200113

31. Kaczanowska S, Beury DW, Gopalan V, Tycko AK, Qin H, Clements ME, et al. Genetically Engineered Myeloid Cells Rebalance the Core Immune Suppression Program in Metastasis. *Cell* (2021) 184:2033–52. doi: 10.1016/j.cell.2021.02.048

32. Escobar G, Barbarossa I, Barbiera G, Norelli M, Genua M, Ranghetti A, et al. Interferon Gene Therapy Reprograms the Leukemia Microenvironment Inducing Protective Immunity to Multiple Tumor Antigens. *Nat Commun* (2018) 9:2896. doi: 10.1038/s41467-018-0351-6

33. Moyes KW, Lieberman NAP, Kreuser SA, Chin H, Winter C, Deutsch G, et al. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy. *Hum Gene Ther* (2017) 28:200–15. doi: 10.1089/hum.2016.060

34. Gardell JL, Matsumoto LR, Chinn H, DeGolier KR, Kreuser SA, Prieskorn B, et al. Human Macrophages Engineered to Secrete a Bispecific T Cell Engager Support Antigen-Dependent T Cell Responses to Glioblastoma. *J Immunother Cancer* (2020) 8:e002102. doi: 10.1136/jitc-2020-002102

35. Cha EB, Shin KK, Seo J, Oh D-B. Antibody-Secreting Macrophages Generated Using Cpg-Free Plasmid Eliminate Tumor Cells Through Antibody-Dependent Cellualr Phagocytosis. *Bmb Rep* (2020) 53:442–7. doi: 10.5483/bmbrep.2020.53.8.024

36. Berraondo P, Etxeberria I, Ponz-Sarvise M, Meler O. Revisiting Interleukin-12 as a Cancer Immunotherapy Agent. *Clin Cancer Res* (2018) 24: clinres.0381.2018. doi: 10.1158/1078-0432.ccr-18-0381

37. Huang Y, Guan Z, Dai X, Shen Y, Wei Q, Ren L, et al. Engineered Macrophages as Near-Infrared Light Activated Drug Vectors for Chemo-Photodynamic Therapy of Primary and Bone Metastatic Breast Cancer. *Nat Commun* (2021) 12:4310. doi: 10.1038/s41467-021-24564-0

38. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clin Cancer Res* (2021) 27:2325–66. doi: 10.1158/1078-0432.ccr-16-1300

39. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS Is a Potent Checkpoint in NK Cell–Mediated Tumor Immunity. *Nat Immunol* (2016) 17:816–24. doi: 10.1038/ni.3470

40. Daher M, Basar R, Gokdemir E, Baran N, Upreti N, Cortes AK, et al. Targeting a Cytokine Checkpoint Enhances the Readout of Armored Cord Blood CAR-NK Cells. *Blood* (2020) 137:624–36. doi: 10.1182/blood.2020007748

41. Hiatt J, Cavero DA, McGregor MJ, Zheng W, Budzik JM, Roth TL, et al. Efficient Generation of Isogenic Primary Human Myeloid Cells Using CRISPR-Cas9 Ribonucleoproteins. *Cell Rep* (2021) 35:109105. doi: 10.1016/j.celrep.2021.109105

42. Freund EC, Lock JY, Oh J, Maculins T, Delamarre L, Bohlen CJ, et al. Efficient Gene Knockout in Primary Human and Murine Myeloid Cells by Non-Viral Delivery of CRISPR-Cas9. *J Exp Med* (2020) 217:1–15. doi: 10.1084/jem.20191692

43. Luo Y-L, Xu C-F, Li H-J, Cao Z-T, Liu J, Wang J-L, et al. Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. *ACS Nano* (2018) 12:994–1005. doi: 10.1021/acsnano.7b07874

44. Ray M, Lee Y-W, Hardie J, Moot R, Tonga YG, Farkas ME, et al. CRISPRMed Macrophages for Cell-Based Cancer Immunotherapy. *Bioconjug Chem* (2018) 29:445–50. doi: 10.1021/acs.bioconjchem.7b00768

45. Williams BB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-Signal Regulatory Protein Alpha (SIRPa) Interaction Is a Therapeutic Target for Human Solid Tumors. *Proc Natl Acad Sci* (2012) 109:6662–7. doi: 10.1073/pnas.1121623109

46. Barclay AN, Berg TKVD. The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target. *Immunology* (2014) 32:25–50. doi: 10.1146/annurev-immunol-032713-120535

47. Bremelris KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, et al. Genetically Engineered Macrophages Persist in Solid Tumors and Locally Deliver Therapeutic Proteins to Activate Immune Responses. *J Immunother Cancer* (2020) 8:e001356. doi: 10.1136/jitc-2020-001356

48. Schnall A, Sloas N, Mullins L, Hume DA, Siavelis P, Stbose M, et al. CAR-Macrophages for Solid Tumors. *J Immunother Cancer* (2019) 7:70. doi: 10.1186/s41467-019-0174-2

49. Costello EK, et al. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy. *Hum Gene Ther* (2017) 28:200–15. doi: 10.1089/hum.2016.060
62. Myers DR, Abram CL, Wádes D, Belwafà A, Welsh AMN, Schulze CJ, et al. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity. Front Immunol (2021) 11:576310. doi: 10.3389/fimmu.2020.576310
63. Gilbert LA, Larson MH, Morsut L, Lui Z, Brar GA, Torres SE, et al. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell (2013) 154:442–51. doi: 10.1016/j.cell.2013.06.044
64. Liu B, Gentili M, Lieb D, Eisenhaure T, Irvine DJ, Hacohen N, et al. Discriminatory Power of Combinatorial Antigen Recognition in Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Cell (2021) 4:6578–80. doi: 10.1016/j.jbiocmat.2021.02.008
65. Dong Y, Zhang S, Gao X, Yin D, Wang T, Li Z, et al. Hif1α is Hypoxia Responsive to Induce Epigenetic Restriction Factor Counteracted by Vpx. Nature (2013) 62:353–8. doi: 10.1038/nature10117
66. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Synthetic Immune Sensing Mechanisms That Discriminate between Self and Zeta Subunits of the Immunoglobulin and T-Cell Receptors. Proc Natl Acad Sci (1993) 90:720–4. doi: 10.1073/pnas.90.2.720
67. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nat Biotechnol (2020) 38:947–53. doi: 10.1038/s41587-020-0462-y
68. Morrisey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric Antigen Receptors That Trigger Phagocytosis. Elife (2017) 7:e36688. doi: 10.7554/elife.36688
69. Niu Z, Chen G, Chang W, Sun P, Luo Z, Zhang H, et al. Chimeric Antigen Receptor-Modified Macrophages Trigger Systemic Anti-Tumor Immunity. J Pathol (2020) 253:247–57. doi: 10.1002/path.5582
70. Wang X, Wang G, Wang N, Liu J, Cai Y, Ren M, et al. A Simple and Efficient Method for the Generation of a Porcine Alveolar Macrophage Cell Line for High-Efficiency Porcine Reproductive and Respiratory Syndrome Virus 2 Infection. J Virol Methods (2019) 274:113727. doi: 10.1016/j.jviromet.2019.113727
71. Stevenson HC, Miller P, Akiyama Y, Favilla T, Beman JA, Herberman R, et al. System for Obtaining Large Numbers of Cryopreserved Human Monocytes Purified by Leukapheresis and Counter-Current Centrifugation Elutriation (CCE). J Immunol Methods (1983) 65:353–63. doi: 10.1016/0022-1759(83)90180-1
72. Hennemann B, Rehm A, Kotte K, Meidenbauer N, Andreesen R. Adoptive Immunotherapy With Tumor-Cytotoxic Macrophages Derived From Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhuGM-CSF) Mobilized Peripheral Blood Monocytes. J Immunother (1997) 20:365–71. doi: 10.1097/00023711-199709000-00005
73. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation. J Immunol (2007) 178:5245–52. doi: 10.4049/jimmunol.178.8.5245
74. Zheng L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent Stem Cell-Derived CAR-Macrophage Cells With Antigen-Dependent Anti-Cancer Cell Functions. J Hematol Oncol (2020) 13:153. doi: 10.1186/s13045-020-00983-2
75. Gabbasov R, Gabitova L, Ohtani Y, Shestova O, Gill S, et al. Abstract 63: Chimeric Antigen Receptor Macrophages (CAR-M) Induce Anti-Tumor Immunity and Synergize With T Cell Checkpoint Inhibitors in Pre-Clinical Solid Tumor Models. Immunology (2021) 81:63–6. doi: 10.1186/1538-7445-ami2021-63
76. Wiskopf K, Weissman IL. Macrophages Are Critical Effectors of Antibody Therapies for Cancer. Mabs (2015) 7:303–10. doi: 10.1080/19420862.2015.1011450
77. Bu Glvd, Bögel M, Otten MA, Oosterling SJ, Kuppen PJ, Meijer S, et al. Experimental Induced Liver Metastases From Colorectal Cancer can Be Prevented by Mononuclear Phagocyte-Mediated Monoclonal Antibody Therapy. J Hepatol (2010) 53:677–85. doi: 10.1016/j.jhep.2010.04.023
78. Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al. Combining CD47 Blockade With Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance. Proc Natl Acad Sci (2021) 118:e2026849118. doi: 10.1073/pnas.2026849118
79. Tseng D, Volkmer JF, Willingham SB, Contras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 Antibody-Mediated Phagocytosis of Cancer by Macrophages Primed an Effective Antitumor T-Cell Response. Proc Natl Acad Sci (2013) 110:11103–8. doi: 10.1073/pnas.1305699110
80. Andrechak IC, Dooling LJ, Discher DE. The Macrophage Checkpoint CD47: Sirpt for Recognition of 'Self' Cells: From Clinical Trials of Blocking
Antibodies to Mechanobiological Fundamentals. Philos Trans R Soc B (2019) 374:20180217. doi: 10.1098/rstb.2018.0217

98. Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, et al. Antagonistic Human Fcγrb (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. Cancer Cell (2015) 27:473–88. doi: 10.1016/j.ccell.2015.03.005

99. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature (2017) 545:495–9. doi: 10.1038/nature22396

100. Emens LA, Middleton G. The Interplay of Immunotherapy and Chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 3:436–43. doi: 10.1158/2326-6066.cir-15-0064

101. Brudno JN, Kochenderfer JN. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. Blood Rev (2018) 34:45–55. doi: 10.1016/j.blre.2018.11.002

102. Netea-Maier RT, Smit JWA, Netea MG. Metabolic Changes in Tumor Cells and Tumor-Associated Macrophages: A Mutual Relationship. Cancer Lett (2018) 413:102–9. doi: 10.1016/j.canlet.2017.10.037

103. Amor C, Feucht J, Leibold J, Ho Y-J, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T Cells Reverse Senescence-Associated Pathologies. Nature (2020) 583:127–32. doi: 10.1038/s41586-020-2403-9

104. Aghajanian H, Kimura T, Runik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting Cardiac Fibrosis With Engineered T Cells. Nature (2019) 573:430–3. doi: 10.1038/s41586-019-1546-2

105. Haideri SS, McKinnon AC, Taylor AH, Kirkwood P, Lewis PJ, O’Dubhhr E, et al. Injection of Embryonic Stem Cell Derived Macrophages Ameliorates Fibrosis in a Murine Model of Liver Injury. NPJ Regener Med (2017) 2:14. doi: 10.1038/s41536-017-0017-0

106. Ding X, Wang J, Huang M, Chen Z, Liu J, Zhang Q, et al. Loss of Microglial Sirpt Promotes Synaptic Pruning in Preclinical Models of Neuronal Degeneration. Nat Commun (2021) 12:2030. doi: 10.1038/s41467-021-22301-1

107. Wong NR, Mohan J, Kopecky BJ, Guo S, Du L, Leid J, et al. Resident Cardiac Macrophages Mediate Adaptive Myocardial Remodeling. Immunity (2021) 54:2072–88. doi: 10.1016/j.immuni.2021.07.003

Conflict of Interest: CS and MK report being employees of Carisma Therapeutics. MK and SG are co-founders of Carisma Therapeutics. MK and SG hold patents related to CAR-M, which have been licensed to Carisma Therapeutics. SG has received research funding from Carisma Therapeutics.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sloas, Gill and Klichinsky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.